NAS:AIMT (USA) Also Trade In: Germany UK

Aimmune Therapeutics Inc $ 34.49 0 (0%)

Volume:
0
Avg Vol (1m):
1,586,088
Market Cap $:
2.26 Bil
Enterprise Value $:
2.09 Bil
P/E (TTM):
0.00
P/B:
12.55
Warning! GuruFocus has detected 2 Severe warning signs with AIMT. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)

Aimmune Therapeutics Inc News and Headlines -

GuruFocus Articles Total 5
  • 1

Swiss giant adds third drug to its portfolio this year

Swiss food and beverage giant Nestle (OTCPK:NSRGY) is paying more than $2 billion for Aimmune Therapeutics, Inc. (AIMT) to bag the California-based company's drug Palforzia, a peanut allergy medication that was approved by the Food and Drug Administration earlier this year.

Nestle already owned more than 25% of Aimmune. The all-cash deal values the company at $2.6 billion. At $34.50 per share, the price amounts to a 174% premium on Aimmune's closing price as of Friday, as Nestlé said in the news release. The purchase is expected to close in the fourth quarter of 2020.

Adding Aimmune will

179 Views    Barry Cohen    2020-09-01 15:27
Guru invests in restructuring cancer drug developer

Billionaire investor Steven Cohen (Trades, Portfolio), head of Point72 Asset Management, disclosed earlier this week his firm established a new 14.91% stake in Verastem Inc. (VSTM).

With the goal of generating superior risk-adjusted returns, the guru’s Stamford, Connecticut-based firm executes a long-short strategy that involves fundamental, bottom-up research processes, macro investments and insights.

According to GuruFocus Real-Time Picks, a Premium feature, Cohen invested in 5.5 million shares of Verastem on Jan. 22, allocating 0.06% of the equity portfolio to the position. He previously exited a smaller holding in the fourth quarter of 2017.

6a1033dcc8d7da320af73cf211e5e4b1.png

261 Views    Sydnee Gatewood    2020-02-05 16:52
Optimism surrounds these companies' launch of drugs in 2020

Of the ten most anticipated drug launches expected this year, two will have the biggest impact on the top line—and possibly the share price--of the companies introducing them.

Aimmune Therapeutics

Heading the list of biggest potential beneficiaries is Aimmune Therapeutics, Inc. (AIMT), whose new drug Palforzia is expected to generate nearly $1.3 billion in sales by 2024. This is a significant development considering that this San Francisco-based biotech has never had a major source of sales revenue.

Palforzia is a food allergy treatment, a field most pharmaceutical companies steer clear of. The drug is a

322 Views    Barry Cohen    2020-02-04 15:22
Here's a look at the latest data from Aimmune and what it means for the company

Aimmune Therapeutics Inc. (NASDAQ:AIMT) is moving this week on the back of some fresh news related to the company’s pipeline.Â

The company announced on Tuesday some data from a phase III trial investigating its lead development asset. The trial in question is called PALISADE and it was put in place to investigate the safety and efficacy of an asset called AR101 in patients with peanut allergy.

Peanut allergy is a major issue in the U.S. and globally right now, with around 1% of people suffering from the condition. That doesn’t sound like a lot right off the bat

78 Views    George Ronan    2018-02-21 17:53
Analysis pinpoints 3 potentially profitable investment prospects

Biotech stocks and those in the pharmaceutical sector could be the next big bet for an investor if indeed we are to go with a recent analysis by Credit Suisse.

According to the firm, there are a number of stocks in these sectors that could offer great returns for investors this year. The analysis comes as companies prepare to release third-quarter results. It’s not a surprise though that Credit Suisse is seeing the health sector as a key investment option for anyone. This year alone the industry has grown by 20%. This was better than the average growth

259 Views    Lovisa Alvin    2017-10-23 14:18

Headlines Total 29
  • 1

2020-11-19
7:02am
2020-11-11
10:38pm
2020-09-23 $ 34.28 (-0.09%)
3:00pm
2020-09-21 $ 34.32 (0.06%)
6:24am
2020-09-16 $ 34.31 (%)
3:00pm
2020-09-08 $ 34.17 (-0.15%)
10:30am
2020-09-01 $ 34.19 (-0.09%)
10:31am
8:12am
2020-08-31 $ 34.22 (171.59%)
3:00pm
8:35am
2020-08-11 $ 13.91 (0.87%)
10:59am
2020-08-06 $ 13.78 (1.92%)
6:34am
2020-07-30 $ 14.04 (1.74%)
5:20pm
2020-07-20 $ 15.96 (0.06%)
6:06am
2020-06-18 $ 19 (%)
8:10am
2020-05-26 $ 17.14 (1.18%)
9:05am
2020-05-18 $ 17.46 (6.85%)
10:44am
2020-05-16
8:03am
2020-05-12 $ 17.9 (1.94%)
11:44pm
2020-05-11 $ 17.9 (1.94%)
4:45pm
2020-05-06 $ 17.3 (3.53%)
1:02am
2020-04-23 $ 16.83 (-1.41%)
10:42am
2020-04-17 $ 16.24 (6.56%)
7:09am
2020-04-16 $ 15.24 (-2.37%)
2:43pm
2020-04-15 $ 15.61 (-1.82%)
6:45am
2020-02-04 $ 29.37 (-11.03%)
9:22am
2019-11-14 $ 26.83 (-2.68%)
8:38am
2018-08-23 $ 27.61 (-1%)
11:07am
2018-02-21 $ 32.21 (-7.87%)
11:53am
Total 29
  • 1